Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026)

Vericel (VCEL) reported Total Non-Current Liabilities of $127.5 million for Q1 2026, little changed on a YoY basis from $127.3 million in Q1 2025, and down 2.98% sequentially from $131.4 million in Q4 2025.

Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

Vericel (VCEL) has 17 years of Total Non-Current Liabilities data on file, last reported at $127.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Total Non-Current Liabilities changed 0.21% year-over-year to $127.5 million; the trailing twelve-month figure through Mar 2026 stood at $127.5 million (changed 0.21% YoY), and the FY2025 full-year result was $131.4 million, down 6.04% from the prior year.
  • Total Non-Current Liabilities declined to $127.5 million in Q1 2026, from $131.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $139.9 million in Q4 2024 to a low of $67.8 million in Q1 2022.
  • A 5-year average of $113.4 million and a median of $127.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities soared 61.98% in 2023 and retreated 6.04% in 2025, its largest moves.
  • Tracing VCEL's Total Non-Current Liabilities over 5 years: stood at $80.7 million in 2022, then soared by 58.06% to $127.6 million in 2023, then rose by 9.62% to $139.9 million in 2024, then decreased by 6.04% to $131.4 million in 2025, then fell by 2.98% to $127.5 million in 2026.
  • Business Quant data shows VCEL's Total Non-Current Liabilities at $127.5 million in Q1 2026, $131.4 million in Q4 2025, and $129.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Vericel 2.30 Bn 2.15 Bn 49.27 Mn 127.52 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 127.52 Mn
Dec 31, 2025 131.43 Mn
Sep 30, 2025 129.74 Mn
Jun 30, 2025 127.14 Mn
Mar 31, 2025 127.25 Mn
Dec 31, 2024 139.88 Mn
Sep 30, 2024 132.69 Mn
Jun 30, 2024 133.66 Mn
Mar 31, 2024 122.61 Mn
Dec 31, 2023 127.61 Mn
Sep 30, 2023 113.68 Mn
Jun 30, 2023 111.76 Mn
Dec 31, 2022 80.73 Mn
Sep 30, 2022 70.18 Mn
Jun 30, 2022 69.98 Mn
Mar 31, 2022 67.78 Mn
Dec 31, 2021 73.20 Mn
Sep 30, 2021 67.32 Mn
Jun 30, 2021 70.79 Mn
Mar 31, 2021 71.20 Mn